Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Cited by (241)

Items 201–241 of 241

1. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies in Non-small Cell Lung Cancer].
   Yulu Wang, Tianqing Chu · 2023 · PubMed Central
2. Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta
   Winson Y. Cheung, Chantelle Carbonell, Vishal Navani, Randeep S. Sangha, Emmanuel M. Ewara, Julia Elia-Pacitti, Sandra Iczkovitz, Tamer N. Jarada, Matthew T. Warkentin · 2024 · Current Oncology
3. A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report
   Ping Liang, Lijuan Qi, Taiyan Guo, Xia You, Chengxu Cui · 2020 · Lung Cancer
4. Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing
   David Allan Moore, Kevin Jon Balbi, Benjamin Poskitt, Philip Bennett · 2021 · Journal of Clinical Pathology
5. EGFR-Directed Therapy in Lung Cancer
   So Yeon Kim, Daniel Botelho Costa, Daisuke Shibahara, Susumu S. Kobayashi, Balázs Halmos · 2023 · Cambridge University Press eBooks
6. Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape
   Surbhi Singhal, David R. Gandara, Jonathan Wesley Riess · 2024 · Journal of Thoracic Oncology
7. [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
   Wensheng Zhou, Wei Zhang, Baohui Han · 2020 · Europe PMC (PubMed Central)
8. EGFR L858R Mutation Combined with EGFR Exon 20 Insertion Mutation in Lung Adenocarcinoma: A Case Report and Literature Review
   文婷 朱 · 2021 · Advances in Clinical Medicine
9. Poor efficacy of immune checkpoint inhibitors plus chemotherapy in the lung cancer patients with EGFR/ERBB2 exon 20 insertion
   Yang Fu, Yue Zheng, Yueyun Chen, Peipei Wang, Qing Li, Ting Liu, Zhenyu Ding · 2022 · Research Square
10. A case of syndrome of inappropriate anti-diuretic hormone during treatment for lung cancer with uncommon EGFR mutations
    Hideki Endoh · 2022 · Journal of Clinical Images and Medical Case Reports
11. Data from Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
    2023
12. Amivantamab (Rybrevant)
    CADTH · 2023 · Canadian Journal of Health Technologies
13. Роль мутації Т790М у першій та другій лініях терапії пацієнтів з EGFR-позитивним недрібноклітинним раком легені
    2023 · Clinical Oncology
14. Comprehensive Analysis of WGCNA - Derived Cancer Associated Fibroblasts Model For Prognosis, Immune Features, and Candidate Drug Development in LUSC
    Rui Sun, Wang Jian · 2023 · Research Square
15. TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China
    Han Wang, Junrui Ma, Jiagui Lu, Yang Wang, Binli Zhang, Hushan Zhang, Hao Peng · 2024 · Biomarkers in Medicine
16. Management of Patients With EGFR Exon 20–Mutant Advanced Non–Small Cell Lung Cancer
    Lova Sun, Melina Elpi Marmarelis, Charu Aggarwal · 2025 · Journal of Clinical Oncology
17. The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysis
    Kejun Liu, Hongrui Li, Quan-Quan Tan, Tao Jiang, Kai‐Cheng Peng, Hua-Jun Chen, Qing Zhou, Xuchao Zhang, Zheng Zheng, Shiyuan Chen et al. · 2025 · Science Progress
18. Molecular testing and targeting for solid tumors with CNS metastases
    Kate Elizabeth Therkelsen, Toni Cao, Meaghan A. Roy-O’Reilly, Brian R. Stocksdale, Seema Nagpal · 2025 · Journal of Neuro-Oncology
19. External quality assessment for EGFR exon 20 mutation testing in patients with non-small cell lung cancer in Spain
    Michele Biscuola, Ana B. Enguita, Yolanda Ruano, Lourdes Gómez, Teresa Hernández‐Iglesias, Antonio Martínez, Santiago Ramón y Cajal, José Luis Rodríguez‐­Peralto · 2025 · Revista Española de Patología
20. Efficacy and safety outcomes of emerging EGFR‑TKIs for patients with non‑small cell lung cancer with EGFR exon 20 insertion mutations: A systematic review and meta‑analysis
    Kang Xie, Jing Wang, Juan Jiang, Zhujun Deng, Qiongxia Hu, Denian Wang · 2025 · Oncology Letters
21. AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions
    Aisha M. Swaih, Sara Talbot, Adriana Savoca, Hannah Thorpe, Vikki Flemington, Benjamin Phillips, Nicola Colclough, William McCoull, Veronika Radeva, David Hargreaves et al. · 2025 · Cell Reports Medicine
22. Optimization of First‐Line Treatment Options in HER2 ‐Altered Lung Adenocarcinoma: A Real‐World Study
    Xiufen Wang, Dahai Wang, Yanxin Sun, Yiling Gan, Juan Li, Xuebing Fu, Yihui Ge, Shuyun Wang, Leirong Wang, Haodong Sun et al. · 2025 · Cancer Medicine
23. Reversed phase HPLC analysis of mobocertinib and its impurities and studies on the structure and biological activity of a new degradation product
    Ronghua Ni, Jisu Qin, Wenyi Wu, Jinqiu Xu, Qunfeng Luo, Liangliang Cai · 2025 · Frontiers in Chemistry
24. Genetic Alteration Profiling in North Macedonian Lung Cancer Patients
    Aleksandar Eftimov, Rubens Jovanović, Slavica Kostadinova-Kunovska, Magdalena Bogdanovska Todorovska, Boro Ilievski, Panche Zdravkovski, Selim Komina, Blagica Krsteska, Simonida Crvenkova, Marija Simonovska et al. · 2025 · Genes
25. Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC
    Feng-Wu Lin, Miao-Qing Zhao, Qiang Wu, Wenqi Wu, Xiao-Ying Wu, Ya Ma, Jia-Ni C. Yin, Meng Yang, Min Gao · 2025 · Genes, Chromosomes and Cancer
26. Comparing the effect of traditional and novel tyrosine kinase inhibitors for epidermal growth factor receptor exon 20 insertions by molecular dynamics simulation
    Kejun Liu, Tao Jiang, Quan-Quan Tan, Hua‐Jun Chen, Qing Wei Zhou, Xuchao Zhang, Zheng Zheng, Yi-Long Wu, Jun Jia, Jin‐Ji Yang · 2025 · Journal of International Medical Research
27. Additional file 1 of Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
    Wu, Qing, Qian, Wei, Xiaoli Sun, Shaojie Jiang · 2022 · Figshare
28. Furmonertinib in lung adenocarcinoma with EGFR exon 20 insertion mutation: A case report of positive outcome
    Qilin Wang, Beilei Zeng, Chuanyu You, Tian Xu, Xinyu Chen, Xueping Yang, Juncai Ye, Yan Gui · 2026 · Medicine
29. Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors
    Adriana Savoca, Diana Zindel, Radosław Polański, Demetrios H. Kostomiris, Mohammad Pirmoradian, Aisha M. Swaih, Sara Talbot, Nicolas Floc’h, Poppy Winlow, Paul R. J. Davey et al. · 2026 · Molecular Cancer Therapeutics
30. Clinical outcomes and survival in patients with NSCLC and EGFR exon 20 mutations: evidence from real-world clinical practice in a retrospective study in Galicia
    B. Campos Balea, Martín Emilio Lázaro Quintela, Ma Carmen Areses Manrique, Cristina Azpitarte Raposeiras, Jorge García, Francisco Javier Afonso Afonso, Manuel Fernández-Bruno, Natalia Fernández Núñez, Raquel Romero Van der Schoot, Lucía Santomé Couto · 2026 · Frontiers in Oncology
31. Amivantamab Monotherapy for Lung Adenocarcinoma With Leptomeningeal Seeding: A Case Report
    Kyeoungseo Park, So Yeon Kim, Sang‐Won Um · 2026 · Respirology Case Reports
32. Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data
    David Michael Waterhouse, Iris Lin, Laura Morrison, Bruno Émond, Marie‐Hélène Lafeuille, Yuxi Wang, Lilián Díaz, Patrick Lefèbvre, Dexter D Waters · 2026 · BMC Pulmonary Medicine
33. Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges
    KIM ABBEGAIL ALDECOA, Zhaohui Arter, Sai‐Hong Ignatius Ou, Misako Nagasaka · 2026 · Lung Cancer Targets and Therapy
34. Nichtkleinzelliges Lungenkarzinom: Mehrere neue Optionen für Therapie des NSCLC mit EGFR-Mutationen
    Josef Gulden · 2026 · Deutsches Ärzteblatt
35. An extremely rare case of congenital pulmonary airway malformation (CPAM) and atypical adenomatous hyperplasia (AAH) with EGFR mutation in a five-year-old girl
    Xiaoyu Liu, Cuomu Zhaxi, Siyu Yang, Lili Jiang, Ping Zhou · 2026 · BMC Pediatrics
36. New Treatment Strategies for Rare Genomic Alterations: EGFR Exon 20 Insertions and HER2-Deregulated Lung Cancer
    Lodovica Zullo, Jordi Remón · 2026 · Cancers
37. Baseline Uncommon EGFR Mutations in Non–Small-Cell Lung Cancer: Structure–Function Classification and Clinical Evidence Interpretation
    Susu Yang, Xiuqin Ma, Yongwei Zhao, Jinhua Ma · 2026 · Cancer Control
38. EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib
    Jiahui Zhang, Yuechen Cui, Qing Ren, Xinyi Wu, Jingjing Li, Xin Liu, Bin Zhang, Dongsheng Yue · 2026 · Clinical & Translational Oncology
39. Analytical and Clinical Validation of the Oncomine Dx Express Test, an In Vitro Diagnostic-Labeled Assay, for Genomic Profiling of FFPE Tumor Samples
    Angie Cheng, Sumitha Nallu, Luming He, April Bigley, Aline Bridi, Emilia Ostrowska, Thilanka Jayaweera, Madhu Jasti, Daniela Garcia, Molly Fehon et al. · 2026 · Molecular Diagnosis & Therapy
40. BindingDB Entry 50018567: Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
    BindingDB · 2024 · UC San Diego
41. Comprehensive Analysis of Next-Generation Sequencing and ARMS-PCR for Detecting EGFR S768 Mutations in Chinese Non-Small Cell Lung Cancer Patients
    Binyue Kou, Shuo Chen, Qin Zheng, Danju Luo, Jun Fan, Bo Huang, Xiu Nie · 2026 · Diagnostics